Donislecel

{{Infobox drug

| image =

| width =

| alt =

| caption =

| pronounce =

| tradename = Lantidra

| Drugs.com =

| MedlinePlus =

| DailyMedID = Donislecel

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Islet cell transplantation via intravenous infusion{{Cite web |url=https://www.fda.gov/media/147529/download |title=Archived copy |website=Food and Drug Administration |access-date=29 June 2023 |archive-date=9 December 2022 |archive-url=https://web.archive.org/web/20221209081246/http://www.fda.gov/media/147529/download |url-status=dead }}{{Cite web |url=https://www.fda.gov/media/147530/download |title=Archived copy |website=Food and Drug Administration |access-date=29 June 2023 |archive-date=19 May 2021 |archive-url=https://web.archive.org/web/20210519000137/https://www.fda.gov/media/147530/download |url-status=dead }}

| class =

| ATC_prefix = A10

| ATC_suffix = XX02

| ATC_supplemental =

| biosimilars =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Lantidra- donislecel solution | website=DailyMed | date=10 July 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24610d9f-0c5a-4f55-93b3-d456300bfd5d | access-date=28 August 2023}}{{cite web | title=Lantidra | website=U.S. Food and Drug Administration (FDA) | date=28 June 2023 | url=https://www.fda.gov/vaccines-blood-biologics/lantidra | access-date=5 July 2023 | archive-date=5 July 2023 | archive-url=https://web.archive.org/web/20230705033633/https://www.fda.gov/vaccines-blood-biologics/lantidra | url-status=dead }}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D12634

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = donislecel-jujn

| IUPAC_name =

| chemical_formula_ref =

| chemical_formula =

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight =

| molecular_weight_comment =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes. Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells. Donislecel is administered as a single infusion into the hepatic (liver) portal vein.

The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.

Donislecel was approved for medical use in the United States in June 2023.

Medical uses

Donislecel is indicated for the treatment of adults with type{{nbsp}}1 diabetes who are unable to approach target glycated hemoglobin (average blood glucose levels) because of current repeated episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education.{{cite press release | title=FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes | website=U.S. Food and Drug Administration (FDA) | date=28 June 2023 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes | archive-url=https://web.archive.org/web/20230628220813/https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes | url-status=dead | archive-date=28 June 2023 | access-date=28 June 2023}} {{PD-notice}}{{cite journal | vauthors = Affan M, Dar MS | title = Donislecel-the first approved pancreatic islet cell therapy medication for type 1 diabetes: a letter to the editor | journal = Irish Journal of Medical Science | volume = 193 | issue = 1 | pages = 231–232 | date = February 2024 | pmid = 37450257 | doi = 10.1007/s11845-023-03464-w }}

The primary mechanism of action of donislecel is believed to be the secretion of insulin by the infused allogeneic islet beta cells. In some people with type{{nbsp}}1 diabetes, these infused cells can produce enough insulin, so the recipient no longer needs to take insulin (by injections or pump) to control their blood sugar levels.

Adverse effects

The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.

History

The safety and effectiveness of donislecel was evaluated in two non-randomized, single-arm studies in which a total of 30 participants with type 1 diabetes and hypoglycemic unawareness received at least one infusion and a maximum of three infusions. Overall, 21 participants did not need to take insulin for a year or more, with eleven participants not needing insulin for one to five years and ten participants not needing insulin for more than five years. Five participants did not achieve any days of insulin independence.

The FDA granted marketing approval of Lantidra to CellTrans, Inc.

References

External links

[https://web.archive.org/web/20210416003429/https://www.fda.gov/media/147525/download FDA Briefing Document], U.S. Food and Drug Administration (FDA)
[https://web.archive.org/web/20210509173401/https://www.fda.gov/media/147597/download Meeting Presentation - Clinical], U.S. FDA Cellular, Tissue, and Gene Therapies Advisory Committee

Category:Orphan drugs

Category:Cell therapies